Maze Therapeutics (MAZE) Assets Average (2025 - 2026)
Maze Therapeutics' (MAZE) quarterly Assets Average came in at $408.4 million in Q1 2026, up 42.46% year-on-year from $286.7 million in Q1 2025, and little changed quarter-over-quarter from $409.6 million in Q4 2025.
Maze Therapeutics (MAZE) Assets Average (2025 - 2026) Analysis & Trends
Maze Therapeutics has disclosed Assets Average across 2 years of filings, most recently posting $408.4 million for Q1 2026.
- Assets Average for Q1 2026 came in at $408.4 million, up 42.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $408.4 million (up 42.46% YoY), and the FY2025 annual result was $318.8 million, changed N/A from the prior year.
- Assets Average came in at $408.4 million for Q1 2026 at Maze Therapeutics, roughly flat from $409.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $409.6 million in Q4 2025 to a low of $286.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 40.89 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 26.03 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 660.38 Mn |
| 10 | Maze Therapeutics | 1.31 Bn | 1.31 Bn | 18.21 Mn | 408.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 408.42 Mn |
| Dec 31, 2025 | 409.59 Mn |
| Sep 30, 2025 | 362.79 Mn |
| Jun 30, 2025 | 318.18 Mn |
| Mar 31, 2025 | 286.69 Mn |